

REFERENCES

- Anonymous. 2000. More information on GHB. The American College of Medical Toxicology. Fairfax, USA. Available from: <http://www.acmt.net> [2004, Feb, 18]
- Arena, C., and Fung, H. L. 1980. Absorption of sodium gamma-hydroxybutyrate and its prodrug gamma-butyrolactone: relationship between in vitro transport and in vivo absorption. *J Pharm Sci* 69(3): 356-358.
- Au, J. L., and Sadee, W. 1980. Activation of Ftorafue [R,S-1-(tetrahydro-2-furanyl)-5-fluorouracil] to 5-fluorouracil and gamma-butyrolactone. *Cancer Res* 40(8 Pt 1): 2814-2819.
- Bamford, D. G., Biggs, D. F., Cuthbert, M. F., Grant, H. N., Lee, G. E., Pulsford, D. W., and Wragg, W. R. 1970. The preparation and intravenous anaesthetic activity of tetrahydrofuran-3-ols. *J Pharm Pharmacol* 22(9): 694-699.
- Barbaccia, M. L., Colombo, G., Africano, D., Carai, M. A., Vacca, G., Melis, S., Purdy, R. H., and Gessa, G. L. 2002. GABA(B) receptor-mediated increase of neurosteroids by gamma-hydroxybutyric acid. *Neuropharmacology* 42(6): 782-791.
- Beardsley, P. M., Balster, R. L., and Harris, L. S. 1996. Evaluation of the discriminative stimulus and reinforcing effects of gammahydroxybutyrate (GHB). *Psychopharmacology (Berl)* 127(4): 315-322.
- Bernasconi, R., Mathivet, P., Bischoff, S., and Marescaux, C. 1999. Gamma-hydroxybutyric acid: an endogenous neuromodulator with abuse potential? *Trends Pharmacol Sci* 20(4): 135-141.

- Bernhardt, D., and Diekmann, H. 1991. Degradation of dioxane, tetrahydrofuran and other cyclic ethers by an environmental Rhodococcus strain. *Appl Microbiol Biotechnol* 36(1): 120-123.
- Bjerke, J. 2002 Tetrahydrofuran graphical pathway map. University of Minnesota. Available from : http://www.labmed.umn.edu/thf/thf_image_map.html [2004, Feb, 18]
- Bourguignon, J. J., Schmitt, M., and Didier, B. 2000. Design and structure-activity relationship analysis of ligands of gamma-hydroxybutyric acid receptors. *Alcohol* 20(3): 227-236.
- Bowery, N. G., Bettler, B., Froestl, W., Gallagher, J. P., Marshall, F., Raiteri, M., Bonner, T. I., and Enna, S. J. 2002. International Union of Pharmacology. XXXIII. Mammalian gamma-aminobutyric acid(B) receptors: structure and function. *Pharmacol Rev* 54(2): 247-264.
- Brittain, R. T., and Handley, S. L. 1967. Temperature changes produced by the injection of catecholamines and 5-hydroxytryptamine into the cerebral ventricles of the conscious mouse. *J Physiol* 192(3): 805-813.
- Cartigny, B., Azaroual, N., Imbenotte, M., Sadeg, N., Testart, F., Richécoeur, J., Vermeersch, G., and Lhermitte, M. 2001. ¹H NMR spectroscopic investigation of serum and urine in a case of acute tetrahydrofuran poisoning. *J Anal Toxicol* 25(4): 270-274.
- Castelli, M. P., Ferraro, L., Mocci, I., Carta, F., Carai, M. A., Antonelli, T., Tanganeli, S., Cignarella, G., and Gessa, G. L. 2003. Selective gamma-hydroxybutyric acid receptor ligands increase extracellular glutamate in the hippocampus, but fail to activate G protein and to produce the sedative/hypnotic effect of gamma-hydroxybutyric acid. *J Neurochem* 87(3): 722-732.

- Chhabra, R. S., Elwell, M. R., Chou, B., Miller, R. A., and Renne, R. A. 1990. Subchronic toxicity of tetrahydrofuran vapors in rats and mice. *Fundam Appl Toxicol* 14(2): 338-345.
- Chhabra, R. S., Herbert, R. A., Roycroft, J. H., Chou, B., Miller, R. A., and Renne, R. A. 1998. Carcinogenesis studies of tetrahydrofuran vapors in rats and mice. *Toxicol Sci* 41(2): 183-188.
- Ciolino, L. A., Mesmer, M. Z., Satzger, R. D., Machal, A. C., McCauley, H. A., and Mohrhaus, A. S. 2001. The chemical interconversion of GHB and GBL: forensic issues and implications. *J Forensic Sci* 46(6): 1315-1323.
- Craig, K., Gomez, H. F., McManus, J. L., and Bania, T. C. 2000. Severe gamma-hydroxybutyrate withdrawal: a case report and literature review. *J Emerg Med* 18(1): 65-70.
- Dean, W. 2003. IAS Bullentin article: a review of the GHB scientific literature. Available from: <http://www.antiaging-center.co/extract/hghbreview.htm> [2003, March, 25]
- de Fiebre, C. M., de Fiebre, N. E., Coleman, S. L., and Forster, M. J. 2004. Comparison of the actions of gamma-butyrolactone and 1,4-butanediol in Swiss-Webster mice. *Pharmacol Biochem Behav* 77(4): 705-710.
- de Vriendt, C. A., van Sassenbroeck, D. K., Rosseel, M. T., van de Velde, E. J., Verstraete, A. G., Vander Heyden, Y., and Belpaire, F. M. 2001. Development and validation of a high-performance liquid chromatographic method for the determination of gamma-hydroxybutyric acid in rat plasma. *J Chromatogr B Biomed Sci Appl*, 752(1): 85-90.
- Delpierre, S., and Jammes, Y. 1997. GABA(B) receptor blockade reduces resistive loading-induced hypoventilation in anesthetized rabbits. *Neurosci Lett* 226(2): 83-86.

- Doherty, J. D., Snead, O. C., and Roth, R. H. 1975. A sensitive method for quantitation of gamma-hydroxybutyric acid and gamma-butyrolactone in brain by electron capture gas chromatography. *Anal Biochem* 69(1): 268-277.
- Draper, A. J., Madan, A., and Parkinson, A. 1997. Inhibition of coumarin 7-hydroxylase activity in human liver microsomes. *Arch Biochem Biophys* 341(1): 47-61.
- Dunham, N. W., and Miya, T. S. 1957. A note on a simple apparatus for detecting neurological deficit in rats and mice. *J Am Pharm Assoc Am Pharm Assoc (Baltim)*, 46(3): 208-209.
- El Sayed, Y. M., and Sadee, W. 1982. Metabolic activation of ftorafur [R,S-1-(tetrahydro-2-furanyl)-5-fluorouracil]: the microsomal oxidative pathway. *Biochem Pharmacol* 31(18): 3006-3008.
- El Sayed, Y. M., and Sadee, W. 1983. Metabolic activation of R,S-1-(tetrahydro-2-furanyl)-5-fluorouracil (ftorafur) to 5-fluorouracil by soluble enzymes. *Cancer Res* 43(9): 4039-4044.
- Elian, A. A. 2001. GC-MS determination of gamma-hydroxybutyric acid (GHB) in blood. *Forensic Sci Int* 122(1): 43-47.
- Elovaara, E., Pfaffli, P., and Savolainen, H. 1984. Burden and biochemical effects of extended tetrahydrofuran vapour inhalation of three concentration levels. *Acta Pharmacol Toxicol (Copenh)* 54(3): 221-226.
- Engel, P. 2000. GHB legislative update. Letter to the editor. *In J Med Toxicol* 3(5): 33.
- Fattore, L., Martellotta, M. C., Cossu, G., and Fratta, W. 2000. Gamma-hydroxybutyric acid: an evaluation of its rewarding properties in rats and mice. *Alcohol* 20(3): 247-256.

- Fattore, L., Cossu, G., Martellotta, M. C., Deiana, S., and Fratta, W. 2001. Baclofen antagonises intravenous self-administration of gamma-hydroxybutyric acid in mice. *Neuroreport* 12(10): 2243-2246.
- Feigenbaum, J. J., and Howard, S. G. 1996. Does gamma-hydroxybutyrate inhibit or stimulate central DA release? *Int J Neurosci* 88(1-2): 53-69.
- Ferrara, S. D., Tedeschi, L., Frison, G., Castagna, F., Gallimberti, L., Giorgetti, R., Gessa, G. L., and Palatini, P. 1993. Therapeutic gamma-hydroxybutyric acid monitoring in plasma and urine by gas chromatography-mass spectrometry. *J Pharm Biomed Anal* 11(6): 483-487.
- Ferraro, L., Tanganelli, S., O'Connor, W. T., Francesconi, W., Loche, A., Gessa, G. L., and Antonelli, T. 2001. gamma-Hydroxybutyrate modulation of glutamate levels in the hippocampus: an in vivo and in vitro study. *J Neurochem* 78(5): 929-939.
- Fishbein, W. N., and Bessman, S. P. 1966. Purification and properties of an enzyme in human blood and rat liver microsomes catalyzing the formation and hydrolysis of gamma-lactones. I. Tissue localization, stoichiometry, specificity, distinction from esterase. *J Biol Chem* 241(21): 4835-4841.
- Fujita, T., and Suzuki, Z. 1973. Enzymatic studies on the metabolism of the tetrahydrofurfuryl mercaptan moiety of thiamine tetrahydrofurfuryl disulfide. 3. Oxidative cleavage of the tetrahydrofuran moiety. *J Biochem (Tokyo)* 74(4): 733-738.
- Galloway, G. P., Frederick, S. L., Staggers, F. E., Jr., Gonzales, M., Stalcup, S. A., and Smith, D. E. 1997. Gamma-hydroxybutyrate: an emerging drug of abuse that causes physical dependence. *Addiction* 92(1): 89-96.
- Galloway, G. P., Frederick-Osborne, S. L., Seymour, R., Contini, S. E., and Smith, D. E. 2000. Abuse and therapeutic potential of gamma-hydroxybutyric acid. *Alcohol* 20(3): 263-269.

- Garnier, R., Rosenberg, N., Puissant, J. M., Chauvet, J. P., and Efthymiou, M. L. 1989. Tetrahydrofuran poisoning after occupational exposure. *Br J Ind Med* 46(9): 677-678.
- Giarmann, N. J., and Roth, R. H. 1964. Differential Estimation of Gamma-Butyrolactone and Gamma-Hydroxybutyric Acid in Rat Blood and Brain. *Science* 145: 583-584.
- Giorgi, O., and Rubio, M. C. 1981. Decreased 3H-L-quinuclidinyl benzilate binding and muscarine receptor subsensitivity after chronic gamma-butyrolactone treatment. *Naunyn Schmiedebergs Arch Pharmacol* 318(1): 14-18.
- Godbout, R., Jelenic, P., Labrie, C., Schmitt, M., and Bourguignon, J. J. 1995. Effect of gamma-hydroxybutyrate and its antagonist NCS-382 on spontaneous cell firing in the prefrontal cortex of the rat. *Brain Res* 673(1): 157-160.
- Goss, J. 2001. Designer drugs. Assess and manage patients intoxicated with ecstasy, GHB or rohypnol--the three most commonly abused designer drugs. *Jems* 26(6): 84-87, 90-83; quiz 94.
- Guidotti, A., and Ballotti, P. L. 1970. Relationship between pharmacological effects and blood and brain levels of gamma-butyrolactone and gamma-hydroxybutyrate. *Biochem Pharmacol* 19(3): 883-894.
- Gupta, M., Greven, R., Jansen, E. E., Jakobs, C., Hogema, B. M., Froestl, W., Snead, O. C., Bartels, H., Grompe, M., and Gibson, K. M. 2002. Therapeutic intervention in mice deficient for succinate semialdehyde dehydrogenase (gamma-hydroxybutyric aciduria). *J Pharmacol Exp Ther* 302(1): 180-187.
- Hara, K., Nagata, T., and Kimura, K. 1987. Forensic toxicological analysis of tetrahydrofuran in body materials. *Z Rechtsmed* 98(1): 49-55.

Hazardous Substances Databank: 2002. Tetrahydrofuran. National Library of Medicine, Bethesda, MD (CD-Rom Version), Micromedex, Inc, Englewood, CO.

Hedou, G., Chasserot-Golaz, S., Kemmel, V., Gobaille, S., Roussel, G., Artault, J. C., Andriamampandry, C., Aunis, D., and Maitre, M. 2000. Immunohistochemical studies of the localization of neurons containing the enzyme that synthesizes dopamine, GABA, or gamma-hydroxybutyrate in the rat substantia nigra and striatum. *J Comp Neurol* 426(4): 549-560.

Hogema, B. M., Gupta, M., Senephansiri, H., Burlingame, T. G., Taylor, M., Jakobs, C., Schutgens, R. B., Froestl, W., Snead, O. C., Diaz-Arrastia, R., Bottiglieri, T., Grompe, M., and Gibson, K. M. 2001. Pharmacologic rescue of lethal seizures in mice deficient in succinate semialdehyde dehydrogenase. *Nat Genet* 29(2): 212-216.

Howard, S. G., and Feigenbaum, J. J. 1997. Effect of gamma-hydroxybutyrate on central dopamine release in vivo. A microdialysis study in awake and anesthetized animals. *Biochem Pharmacol* 53(1): 103-110.

Imbenotte, M., Azaroual, N., Cartigny, B., Vermeersch, G., and Lhermitte, M. 2003. Identification and quantitation of xenobiotics by ¹H NMR spectroscopy in poisoning cases. *Forensic Sci Int* 133(1-2): 132-135.

Irwin, R. D. 2006. A review of evidence leading to the prediction that 1,4-butanediol is not a carcinogen. *J Appl Toxicol* 26(1): 72-80.

Itzhak, Y., and Ali, S. F. 2002. Repeated administration of gamma-hydroxybutyric acid (GHB) to mice: assessment of the sedative and rewarding effects of GHB. *Ann N Y Acad Sci* 965: 451-460.

- Jang, C. G., Lee, S. Y., Yoo, J. H., Yan, J. J., Song, D. K., Loh, H. H., and Ho, I. K. 2003. Impaired water maze learning performance in mu-opioid receptor knockout mice. *Brain Res Mol Brain Res* 117(1): 68-72.
- Kaopatumtip, S. 2003. A deadly brew :Available from: <http://www.bangkokpost.net/eyetpress/a030703.html> [2003, Oct 14].
- Karl, T., Pabst, R., and von Horsten, S. 2003. Behavioral phenotyping of mice in pharmacological and toxicological research. *Exp Toxicol Pathol* 55(1): 69-83.
- Kawalek, J. C., and Andrews, A. W. 1980. The effect of solvents on drug metabolism in vitro. *Drug Metab Dispos* 8(6): 380-384.
- Kerrigan, S. 2001a. GHB and precursors (part I): Use, effects, pharmacology. *Clinical & Forensic Toxicology News* : 1-8.
- Kerrigan, S. 2001b. GHB and precursors (part II): Management and analysis. *Clinical & Forensic Toxicology News* : 1-8.
- Kohlweyer, U., Thiemer, B., Schrader, T., and Andreesen, J. R. 2000. Tetrahydrofuran degradation by a newly isolated culture of *Pseudonocardia* sp. strain K1. *FEMS Microbiol Lett* 186(2): 301-306.
- Lanigan, R. S., and Yamarik, T. A. 2002. Final report on the safety assessment of BHT(1). *Int J Toxicol*, 21 Suppl 2: 19-94.
- LeBeau, M. A., Miller, M. L., and Levine, B. 2001. Effect of storage temperature on endogenous GHB levels in urine. *Forensic Sci Int* 119(2): 161-167.
- Leppänen, P. K., Ewalds-Kvist, S. B., and Selander, R. K. 2005. Mice selectively bred for open-field thigmotaxis: life span and stability of the selection trait. *J Gen Psychol* 132(2): 187-204.

- Lettieri, J., and Fung, H. L. 1978. Improved pharmacological activity via pro-drug modification: comparative pharmacokinetics of sodium gamma-hydroxybutyrate and gamma-butyrolactone. *Res Commun Chem Pathol Pharmacol* 22(1): 107-118.
- Lettieri, J. T., and Fung, H. L. 1979. Dose-dependent pharmacokinetics and hypnotic effects of sodium gamma-hydroxybutyrate in the rat. *J Pharmacol Exp Ther* 208(1): 7-11.
- Li, J., Stokes, S. A., and Woeckener, A. 1998. A tale of novel intoxication: seven cases of gamma-hydroxybutyric acid overdose. *Ann Emerg Med* 31(6): 729-736.
- Lingenhoehl, K., Brom, R., Heid, J., Beck, P., Froestl, W., Kaupmann, K., Bettler, B., and Mosbacher, J. 1999. Gamma-hydroxybutyrate is a weak agonist at recombinant GABA(B) receptors. *Neuropharmacology* 38(11): 1667-1673.
- Maitre, M., Hechler, V., Vayer, P., Gobaille, S., Cash, C. D., Schmitt, M., and Bourguignon, J. J. 1990. A specific gamma-hydroxybutyrate receptor ligand possesses both antagonistic and anticonvulsant properties. *J Pharmacol Exp Ther* 255(2): 657-663.
- Maitre, M. 1997. The gamma-hydroxybutyrate signalling system in brain: organization and functional implications. *Prog Neurobiol* 51(3): 337-361.
- Malley, L. A., Christoph, G. R., Stadler, J. C., Hansen, J. F., Biesemeier, J. A., and Jasti, S. L. 2001. Acute and subchronic neurotoxicological evaluation of tetrahydrofuran by inhalation in rats. *Drug Chem Toxicol* 24(3): 201-219.

- Marcus, R. J., Winters, W. D., and Hultin, E. 1976. Neuropharmacological effects induced by butanol, 4-hydroxybutyrate, 4-mercaptoputyric acid thiolactone, tetrahydrofuran, pyrrolidine, 2-deoxy-d-glucose and related substances in the rat. *Neuropharmacology* 15(1): 29-38.
- Martellotta, M. C., Fattore, L., Cossu, G., and Fratta, W. 1997. Rewarding properties of gamma-hydroxybutyric acid: an evaluation through place preference paradigm. *Psychopharmacology (Berl)* 132(1): 1-5.
- Mason, P. E., and Kerns, W. P., 2nd. 2002. Gamma hydroxybutyric acid (GHB) intoxication. *Acad Emerg Med* 9(7): 730-739.
- Mathivet, P., Bernasconi, R., De Barry, J., Marescaux, C., and Bittiger, H. 1997. Binding characteristics of gamma-hydroxybutyric acid as a weak but selective GABA_B receptor agonist. *Eur J Pharmacol* 321(1): 67-75.
- Moody, D. E. 1991. The effect of tetrahydrofuran on biological systems: does a hepatotoxic potential exist? *Drug Chem Toxicol* 14(4): 319-342.
- Morris, J. A. 2000. Potential for Gamma-butyrolactone synthesis from tetrahydrofuran and 1,4-butanediol. *Microgram* 33 (1): 321-324. Available from: <http://www.rhodium.ws/chemistry/gbl/synthesis.microgram.html> [2003, August, 9].
- Nation Multimedia Group. 2003. Deadly wine: batch ‘was US bound’. Available from: <http://www.nationmultimedia.com/page.arcview.php3>. [2003, Oct 14].
- National Occupational Health and Safety Commission (NOHSC): Commonwealth of Australia: 2003. Tetrahydrofuran: Exposure Standards. Available from: <http://www.noehsc.gov.au/OHSInformation/Databases/ExposureStandards/az/Tetrahydrofuran.htm> [2003, June 9].

- National Toxicology Program. 1998. NTP toxicology and carcinogenesis studies of tetrahydrofuran (CAS No. 109-99-9) in F344/N rats and B6C3F1 mice (inhalation studies). *Natl Toxicol Program Tech Rep Ser* 475: 1-244.
- Nicholson, K. L., and Balster, R. L. 2001. GHB: a new and novel drug of abuse. *Drug Alcohol Depend* 63(1): 1-22.
- Nowycky, M. C., and Roth, R. H. 1979. Chronic gamma-butyrolactone (GBL) treatment: a potential model of dopamine hypoactivity. *Naunyn Schmiedebergs Arch Pharmacol* 309(3): 247-254.
- Olpe, H. R., Karlsson, G., Pozza, M. F., Brugger, F., Steinmann, M., Van Riezen, H., Fagg, G., Hall, R. G., Froestl, W., and Bittiger, H. 1990. CGP 35348: a centrally active blocker of GABAB receptors. *Eur J Pharmacol* 187(1): 27-38.
- Ong, C. N., Chia, S. E., Phoon, W. H., and Tan, K. T. 1991. Biological monitoring of occupational exposure to tetrahydrofuran. *Br J Ind Med* 48(9): 616-621.
- Quang, L. S., Desai, M. C., Kraner, J. C., Shannon, M. W., Woolf, A. D., and Maher, T. J. 2002. Enzyme and receptor antagonists for preventing toxicity from the gamma-hydroxybutyric acid precursor 1,4-butanediol in CD-1 mice. *Ann NY Acad Sci* 965: 461-472.
- Redrobe, J. P., Dumont, Y., Herzog, H., and Quirion, R. 2003. Neuropeptide Y (NPY) Y2 receptors mediate behaviour in two animal models of anxiety: evidence from Y2 receptor knockout mice. *Behav Brain Res* 141(2): 251-255.
- Rhodium. 2003. GHB (gamma-hydroxybutyrate) synthesis FAQ. Available from: <http://www.rhodium.ws/chemistry/ghb.html> [2003, Feb, 14].

- Roth, R. H., and Giarman, N. J. 1966. Gamma-butyrolactone and gamma-hydroxybutyric acid I. Distribution and metabolism. *Biochem Pharmacol* 15: 1333-1348.
- Roth, R. H., and Giarman, N. J. 1970. Natural Occurrence of gamma-hydroxybutyrate in mammalian brain. *Biochem Pharmacol* 19: 1087-1093.
- Roth, R. H., Doherty, J. D., and Walters, J. R. 1980. Gamma-hydroxybutyrate: a role in the regulation of central dopaminergic neurons? *Brain Res* 189(2): 556-560.
- Roux, S., Froger, C., Porsolt, R.D., Valverde, O., and Maldonado, R. Unit 10.4 Place preference test in rodents in *Current Protocols in Pharmacology* John Wiley & Sons, Inc. 2002: 10.4.1-10.4.14.
- Schmidt, C., Gobaille, S., Hechler, V., Schmitt, M., Bourguignon, J. J., and Maitre, M. 1991. Anti-sedative and anti-cataleptic properties of NCS-382, a gamma-hydroxybutyrate receptor antagonist. *Eur J Pharmacol* 203(3): 393-397.
- Schmidt-Mutter, C., Pain, L., Sandner, G., Gobaille, S., and Maitre, M. 1998. The anxiolytic effect of gamma-hydroxybutyrate in the elevated plus maze is reversed by the benzodiazepine receptor antagonist, flumazenil. *Eur J Pharmacol* 342(1): 21-27.
- Serra, M., Sanna, E., Foddi, C., Concas, A., and Biggio, G. 1991. Failure of gamma-hydroxybutyrate to alter the function of the GABA_A receptor complex in the rat cerebral cortex. *Psychopharmacology (Berl)* 104(3): 351-355.
- Sircar, R., and Basak, A. 2004. Adolescent gamma-hydroxybutyric acid exposure decreases cortical N-methyl-D-aspartate receptor and impairs spatial learning. *Pharmacol Biochem Behav* 79(4): 701-708.

- Snead, O. C., 3rd. 1996. Relation of the [³H] gamma-hydroxybutyric acid (GHB) binding site to the gamma-aminobutyric acid B (GABA_B) receptor in rat brain. *Biochem Pharmacol* 52(8): 1235-1243.
- Snead, O. C., III. 1991. Effect of gamma-crotonolactone in experimental models of generalized absence seizures. *Brain Res* 543(1): 10-14.
- Sun, M. K., and Alkon, D. L. 2003. Open space swimming test to index antidepressant activity. *J Neurosci Methods* 126(1): 35-40.
- Swinyard, E. A., Brown, W. C., and Goodman, L. S. 1952. Comparative assays of antiepileptic drugs in mice and rats. *J Pharmacol Exp Ther* 106(3): 319-330.
- Tallarida, R. J., and Murray, R.B. Manual of pharmacologic calculations with computer programs, 2nd ed., Springer, New York, 1987.
- Teter, C. J., and Guthrie, S. K. 2001. A comprehensive review of MDMA and GHB: two common club drugs. *Pharmacotherapy* 21(12): 1486-1513.
- The Good Reverend Drone. 2003. References for the synthesis of Gamma-butyrolactone from tetrahydrofuran. Available from: <http://www.rhodium.ws/chemistry/thf2gbl.html>. [2003, June, 15].
- The Nation. Pattaya poisoning: police charge woman. 2003, July, 1. Available from: <http://www.thaivisa.com/index.php> [2003, Aug, 15].
- Thiemer, B., Andreesen, J. R., and Schrader, T. 2001. The NADH-dependent reductase of a putative multicomponent tetrahydrofuran monooxygenase contains a covalently bound FAD. *Eur J Biochem* 268(13): 3774-3782.

- Thiemer, B., Andreesen, J. R., and Schrader, T. 2003. Cloning and characterization of a gene cluster involved in tetrahydrofuran degradation in *Pseudonocardia* sp. strain K1. *Arch Microbiol* 179(4): 266-277.
- Thomson MICROMEDEX. 2004a. Meditext managements: Tetrahydrofuran. *Micromedex® Healthcare series* Vol. 119.3.
- Thomson MICROMEDEX. 2004b. Poisindex® managements: Gamma hydroxybutyric acid and related agents. *Micromedex® Healthcare series* Vol. 119.3.
- Tunnicliff, G. 1997. Sites of action of gamma-hydroxybutyrate (GHB)--a neuroactive drug with abuse potential. *J Toxicol Clin Toxicol* 35(6): 581-590.
- Ullrich, V., Weber, P., and Wollenberg, P. 1975. Tetrahydrofuran - an inhibitor for ethanol-induced liver microsomal cytochrome P450. *Biochem Biophys Res Commun* 64(3): 808-813.
- Villain, M., Cirimele, V., Ludes, B., and Kintz, P. 2003. Ultra-rapid procedure to test for gamma-hydroxybutyric acid in blood and urine by gas chromatography-mass spectrometry. *J Chromatogr B Analyt Technol Biomed Life Sci* 792(1): 83-87.
- Walters, J. P. 2002. ONDCP Drug Policy Information Clearinghouse Fact sheet :Gamma hydroxybutyrate (GHB). Nov:1-4. Available from: <http://www.whitehousedrugpolicy.gov> [2003, June 15].
- Wisotsky, A. 1999. GHB letters. Available from: <http://www.ceri.com/wisotsky.htm>. [2003, Sep, 8].
- Woolverton, W. L., Rowlett, J. K., Winger, G., Woods, J. H., Gerak, L. R., and France, C. P. 1999. Evaluation of the reinforcing and discriminative stimulus effects of gamma-hydroxybutyrate in rhesus monkeys. *Drug Alcohol Depend* 54(2): 137-143.

Wong, C. G., Gibson, K. M., and Snead, O. C., 3rd. 2004. From the street to the brain: neurobiology of the recreational drug gamma-hydroxybutyric acid. *Trends Pharmacol Sci* 25(1): 29-34.

Yamada, K., Noda, Y., Hasegawa, T., Komori, Y., Nikai, T., Sugihara, H., and Nabeshima, T. 1996. The role of nitric oxide in dizocilpine-induced impairment of spontaneous alternation behavior in mice. *J Pharmacol Exp Ther* 276(2): 460-466.

VITAE

Miss Nuttiya Werawattanachai was born on June 27, 1971 in Ubon Ratchathani Province. She graduated with the Bachelor degree in Nursing from Mahidol University in 1993 and the Master's degree in Pharmacology from Chulalongkorn University in 1995. She has worked as an instructor at the Faculty of Pharmaceutical Sciences, Ubon Ratchathani University, Ubon Ratchathani, Thailand since 1996.

